AbCellera founder and CEO Carl Hansen (L) and Rallybio CEO Martin Mackay
December 1, 2022 06:33 AM EST
Deals
R&D

Rally­bio, Ab­Cellera form new part­ner­ship around an­ti­bod­ies for rare dis­ease

Tyler Patchen

News Reporter

Two biotechs that have been work­ing heav­i­ly on dif­fer­ent stages of an­ti­body can­di­date de­vel­op­ment over the past sev­er­al years are look­ing to work to­geth­er to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Biotech seed rounds sink to low­est lev­el in years as in­dus­try slump drags on

US drugs re­ly heav­i­ly on in­gre­di­ents made over­seas, new re­port shows

Phar­ma's wins and loss­es in Trump's sprawl­ing ex­ec­u­tive or­der on drug prices

Ex­clu­sive: VelaV­i­go inks an­oth­er US biotech deal as Chi­na drug de­vel­op­ment scene booms

Sarep­ta los­es CMO to RNA edit­ing up­start; An­oth­er wave of per­son­nel moves at Dyne

sponsored

New York-based part­ner­ship sets the stan­dard for ex­pand­ing clin­i­cal tri­al ac­cess for un­der­served and di­verse ...

A service from the Financial Times